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Summary There is increasing evidence to indicate that 06-methyldeoxyguanosine (06-MedG) formation in
DNA is a critical cytotoxic event following exposure to certain anti-tumour alkylating agents and that the
DNA repair protein 06-alkylguanine-DNA alkyltransferase (ATase) can confer resistance to these agents. We
recently demonstrated a wide inter-individual variation in the depletion and subsequent regeneration of ATase
in human peripheral blood lymphocytes following sequential DTIC (400mg m2) and fotemustine
(100mgm 2) treatment, with the nadir ATase activity occurring approximately 4h after DTIC administra-
tion. We have now measured the formation and loss of 06-methyldeoxyguanosine (06-MedG) in the DNA of
peripheral leucocytes of eight patients receiving this treatment regimen. 06-MedG could be detected within I h
and maximal levels occurred approximately 3-5 h after DTIC administration. Following the first treatment
cycle, considerable inter-individual variation was observed in the peak 06-MedG levels, with values ranging
from 0.71 to 14.3fimol of 06-MedG per mol of dG (6.41 ± 5.53, mean ± s.d.). Inter- and intra-individual
variation in the extent of 06-MedG formation was also seen in patients receiving additional treatment cycles.
This may be a consequence of inter-patient differences in the capacity for metabolism of DTIC to release a
methylating intermediate and could be one of the determinants of clinical response. Both the pretreatment
ATase levels and the extent ofATase depletion were inversely correlated with the amount of 06-MedG formed
in leucocyte DNA when expressed either as peak levels (r = - 0.59 and - 0.75 respectively) or as the area
under the concentration-time curve (r = -0.72 and -0.73 respectively). One complete and one partial clinical
response were seen, and these occurred in the two patients with the highest 06-MedG levels in the peripheral
leucocyte DNA, although the true significance of this observation has yet to be established.
Dacarbazine (5-(3,3-dimethyl-1-triazeno)imidazole-4-carbox-
amide; DTIC) is considered the single most effective chemo-
therapeutic agent available for the treatment of metastatic
melanoma (Comis, 1976; Balch et al., 1989). It undergoes
metabolic N-demethylation to give the monomethyl triazene,
5-(3-methyl-1-triazeno)imidazole-4-carboxamide (MTIC), which
methylates cellular macromolecules including DNA. Among
the 12 DNA lesions so formed, 06-methyldeoxyguanosine
(06-MedG) is thought to be the principal cytotoxic product
(Meer et al., 1986). It has been shown that resistance to
MTIC and related agents involves the activity of the DNA
repair protein 06-alkylguanine-DNA alkyltransferase
(ATase), which transfers the methyl group from 06-MedG to
an internal cysteine residue in an autoinactivating, stoichio-
metric reaction (Hayward & Parsons, 1984; Gibson et al.,
1986; Catapano et al., 1987; D'Incalci et al., 1988; Lunn &
Harris, 1988; Foster et al., 1990). The strongest evidence for
the cytotoxic effects of 06-alkylguanine on DNA comes from
experiments which show that the expression of a transfected
prokaryotic or eukaryotic ATase cDNA in mammalian cells
protects them against the toxic effects of these agents (Bren-
nand & Margison, 1986; Kataoka et al., 1986; Samson et al.,
1986; Jelinek et al., 1988; Kaina et al., 1991).
We recently examined the levels of ATase in human
peripheral lymphocytes following combination therapy with
DTIC and the chloroethylating agent, fotemustine. ATase
activity was depleted and the rate and extent of ATase
depletion was patient, dosage and cycle dependent, with the
nadir of ATase activity occurring 4-5 h after DTIC adminis-
tration (Lee et al., 1991, 1993a). These findings have been
attributed to autoinactivation of ATase during the repair of
06-MedG formed in lymphocyte DNA. It was also shown
that fotemustine administration was not associated with
ATase depletion in peripheral lymphocytes (Lee et al.,
1993a).
The present study investigates the kinetics of formation
and loss of 06-MedG in total blood leucocyte DNA to
explore possible relationships with changes in ATase levels in
peripheral lymphocytes following DTIC administration.
These factors may have important therapeutic implications,
particularly in combination with the effects of administration
of a nitrosourea for which drug resistance can also involve
ATase activity (D'Incalci et al., 1988; Pegg, 1990).
Materials and methods
Patients and blood samples
Details of the individuals studied are shown in Table I. Each
patient received DTIC (400 mg m-2) by i.v. infusion over
10min followed 4 h later by fotemustine (100 mgm2) given
as a 30 min i.v. infusion. The treatment was repeated every 4
weeks except for patient F.E. (with brain metastasis), who
received an additional treatment on day 8. Blood samples
(20 ml) were collected just before therapy and at 1, 2, 3, 4, 5,
6 and 18 h after DTIC administration from eight patients in
the first treatment cycle. A further five sets of blood samples
were collected from four patients who returned for subse-
quent treatments. Each sample was divided into two univer-
sal containers (10 ml each) containing 0.5 ml of 0.5% EDTA,
pH 8.0. One half was stored at - 20'C prior to DNA extrac-
tion and radioimmunoassay for 06-MedG, while the second
half was kept at 4°C before isolation of lymphocytes for
ATase assays. Approval was given by the local ethical com-
mittee and informed consent was obtained from all patients
prior to the study.
DNA isolation
Blood samples (10 ml) were thawed, combined with 10 ml of
lysis buffer (155 mM ammonium chloride, 10 mM potassium
bicarbonate, 2 mM EDTA, pH 7.5) and allowed to stand at
4°C for 30min. Nuclei were collected by centrifugation at
625 g for 10min at 4'C, resuspended in 1.5 ml of 75 mM
sodium chloride, 24 mM EDTA, pH 7.5, and lysed by the
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Table I Patient characteristics
Patient/treatment ATase activity 06-MedG
cycle Age/sex Metastatic sites Responsea Pretreatment Nadir Peak amountb AUCc
I.P./1 66/F Nodes/parotid gland CR 241 137 14.3 (h3)d 28.5
I.P./2 138 90 24.7 (h3) 74.7
I.P./3 189 77 7.6 (hS) 57.7
K.R./I 68/F Lung/ovaries PR 258 123 12.8 (h3) 27.3
K.R./2 242 81 1.1 (h5) 10.9
F.E/I 61/M Lung/brain NE 278 184 7.7 (h4) 48.2
F.E./2 168 61 8.3 (h2) 110.3
G.B./I 53/M Skin/nodes/lung PD 217 72 5.7 (h5) 62.2
G.B./2 191 118 5.6 (h3) 76.0
J.G./1 54/M Skin/liver PD 400 196 1.0 (h3) 12.5
M.B./i 53/F Subcutaneous/nodes/bone/ PD 309 163 2.0 (h3) 24.9
soft tissue
M.L./I 73/M Skin/lung/liver/spleen PD 5.6 (h3) 68.0
M.H./1 40/M Nodes/soft tissue PD 263 55 0.7 (h3) 2.0
aCR, complete response; PR, partial response; PD, progressive disease; NE, not evaluable. b Peak amount of 06-MedG in total peripheral
leucocyte DNA (gmol mol-' dG). cArea under curve of 06-MedG qsmol mol-' dG) vs time (hours) from 0 to 18 h except for sample K.R./i,
which was integrated from 0 to 4 h. Values calculated following the trapezoid rule using Sigmaplot 5.0 graph-plotting software. dTime to reach
peak 06-MedG in total peripheral leucocyte DNA (hours).
addition of sodium dodecyl sulphate (SDS) to a final concen-
tration of 1%. The lysate was then incubated overnight at
37°C in the presence of proteinase K (0.1 mgml-'). The
following day, 1.5 ml of phenol (saturated with 100 mM Tris-
HCI, pH 8.0) was added and after shaking at room tempera-
ture for 10 min the mixture was centrifuged at 625g for
5min. The upper, aqueous phase was re-extracted with
phenol as above and residual protein was removed from the
final aqueous phase by extraction with 1.5 ml of chloroform-
isoamyl alcohol (25:1, v/v). DNA was precipitated by the
addition of sodium acetate (10 tld of a saturated solution) and
3.75 ml of ethanol. Following sequential washing in 70%
ethanol, ethanol, ethanol-ether (1:1, v/v) and ether, residual
solvent was removed by evaporation in a stream of nitrogen.
The yield of DNA was 0.2-1.0 mg and the product was free
from RNA contamination.
06-alkylguanine-DNA alkyltransferase assay
ATase activity was measured in cell-free extracts of
peripheral blood lymphocytes by monitoring the transfer of
radioactive methyl groups from substrate DNA to protein.
The substrate was prepared by in vitro methylation of calf
thymus DNA using nitroso-[3H]methylurea and activity is
expressed as fmol of [3H]methyl transferred per mg ofprotein
in the extract (Lee et al., 1991).
06-Methyldeoxyguanosine analysis
The procedure used for the determination of 06-MedG in
DNA has been described in detail elsewhere (Wild et al.,
1983; Hall et al., 1991) and is presented here in outline only.
DNA was digested enzymatically to nucleosides before ion-
exchange chromatography using Aminex A7 resin (BioRad,
Hemel Hempstead, UK). The four major deoxynucleosides
were separated from 06-MedG by this procedure and were
quantified by peak area integration. The putative 06-MedG-
containing fractions and control fractions (i.e. similar
volumes of buffer from a nucleoside-free region of the col-
umn elution profile) were analysed by radioimmunoassay
using a monoclonal antibody to 06-MedG (Wild et al., 1983).
The results are expressed relative to the amount of dG in the
DNA sample. The lower limit of detection using these small
amounts of DNA was -0.41 mol of 06-MedG per mol of
dG.
Where sufficient sample remained, duplicate radioimmuno-
assay (RIA) determinations were performed, and these
indicated an inter-assay variation which was generally
<± 20%. At values approaching the limit of detection,
greater inter-assay variation was apparent, and this app-
roached ± 35% as previously reported (Badawi et al., 1992).
Assay variation has also been monitored by inclusion of a
control sample which varied from 0.072 to 0.102 pmol of
06-MedG (0.086 ± 0.010, mean ± s.d.) over a period of
approximately 3 months.
Results
06-Alkylguanine-DNA alkyltransferase activity
The data regarding the changes in ATase activity during
combination chemotherapy with DTIC and fotemustine have
been reported previously as mean values of a group of
patients (Lee et al., 1993a). Here, we present the pretreatment
and nadir (i.e. the minimum level reached during therapy)
lymphocyte ATase activity on an individual basis for all the
patients in the present study (Table I). Prior to the first cycle
of chemotherapy, ATase activity among the different patients
varied by a factor of approximately 2 (range: 217-400 fmol
mg-' protein) with a mean value of 289 ± 60 fmolmg-' pro-
tein. This value fell to a mean nadir level of 133 ± 54 fmol
mg-' protein 4-5 h after treatment and inter-individual
variation at this time increased to 3.6-fold (range:
55-196 fmolmg-' protein). Following subsequent cycles of
therapy, both the mean pretreatment and mean nadir levels
of ATase activity (186 ± 38 and 85 ± 21 respectively) were
reduced by a factor of 1.6 when compared with cycle 1.
06-Methyldeoxyguanosineformation in leucocyte DNA
06-MedG could be detected in total blood leucocyte DNA
shortly after DTIC administration in all patients studied at
cycles 1, 2 or 3 of treatment (Figure 1). The kinetics of DNA
methylation was broadly similar in all cases: a post-treatment
peak in 06-MedG formation occurred at 3-5 h and was
followed by a decline in adduct level (Figure 1). However, in
some cases (e.g. F.E./1, Figure la) there was a tendency for
06-MedG levels to rise again towards the end of the treat-
ment cycle.
There was an approximately 20-fold inter-individual varia-
tion in the 06-MedG maxima both among patients in cycle 1
(range: 0.7-14.3 jsmol of 06-MedG per mol of dG; 6.4 ± 5.5,
mean ± s.d.) and in cycle 2 (range: 1.1-24.7jimol of 06_
MedG per mol of dG; 9.4 ± 8.9, mean ± s.d.). Of the four
patients who returned for subsequent courses of DTIC06-METHYLDEOXYGUANOSINE IN HUMAN LEUCOCYTE DNA 855
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Figure 1 06-MedG levels in peripheral leucocyte DNA in eight
patients at various times during cycle 1 (a and b) or subse-
quent cycles (c) of sequential DTIC (400 mgm-2)/fotemustine
(100 mg mr-2) chemotherapy for metastatic melanoma. Arrows
indicate the time at which fotemustine was administered.
therapy, two (F.E. and G.B.) achieved peak adduct levels
similar to those observed in cycle 1, a third (K.R.) showed an
approximately 11-fold reduction and in the fourth patient
(I.P.) the peak 06-MedG level in cycles 2 and 3 was increased
and decreased, respectively, relative to that observed for cycle
1 (Figure 1 and Table I).
In all but one case (M.H./1), 06-MedG persisted in the
DNA for at least 18 h. One individual (F.E.; with brain
metastases) returned on day 8 for a second DTIC treatment
and 06-MedG was detected in leucocyte DNA at this time at
a level of 1.3 smol of 06-MedG per mol of dG (Figure Ic).
For the remaining cases in which repeat therapy was given at
28 day intervals, residual 06-MedG from previous exposure
to DTIC was not detected.
A combined measure of 06-MedG formation and its per-
sistence was obtained for each patient by integration of the
area under the 06-MedG concentration-time curve (AUC;
Figure 1). The values obtained are shown in Table I. Again,
considerable inter-individual variation was apparent with 34-
fold and 10-fold differences between the highest and lowest
values for cycles 1 and 2 respectively. In general, leucocyte
DNA from patients returning for subsequent courses of
chemotherapy tended to be more extensively methylated (in
terms of the 06-MedG AUC) than in patients receiving the
first DTIC treatment (Table I).
Relationship between lymphocyte ATase activity and leucocyte
06-methyldeoxyguanosineformation in peripheral blood
The nadir of ATase activity in peripheral lymphocytes occur-
red 4-5 h after DTIC administration, and this coincided with
the peak of DNA methylation in the leucocytes. An inverse
correlation was seen between the pretreatment ATase activity
and the amount of 06-MedG formed in DNA expressed as
either the maxima or the AUC (Figure 2a and c respectively).
The extent of lymphocyte ATase depletion (i.e. the difference
between pretreatment and nadir ATase activity) was similarly
related to the 06-MedG maxima and the AUC (Figure 2b
and d respectively). On the other hand, no correlation
between the nadir ATase activity level and the extent of
06-MedG formed in DNA was apparent.
Discussion
DTIC is a prodrug that requires metabolic activation to
produce the methylating agent MTIC which can then react
with DNA (Meer et al., 1986). The present study demon-
strates the presence of 06-MedG in the DNA of peripheral
leucocytes from patients receiving combined DTIC/fotemus-
tine therapy and hence the ability of these patients to activate
DTIC.
Maximum levels of 06-MedG were observed 3-5 h after
DTIC administration, and this coincided with the nadir in
ATase activity in peripheral lymphocytes (Lee et al., 1993a).
Interestingly, DNA single-strand breaks occurring in
peripheral blood lymphocytes are also maximal approxi-
mately 5 h after DTIC administration (Walles & Ringborg,
1991).
In treatment cycle 1 there was an approximately 20-fold
inter-individual variation in the 06-MedG maxima, which
was also evident in the group of patients that went on to
receive further courses of therapy (Figure 1 and Table I). The
06-MedG AUC gives a combined measure of the formation
and persistence of 06-MedG, and these values also show
large inter-individual variations, with differences of 34-fold
and 10-fold for cycle 1 and subsequent cycles respectively. In
some patients, an increase in 06-MedG level was seen at
18 h, and while this effect may be accounted for to some
extent by experimental variation (see Materials and methods)
reasons for the larger increases seen in patient F.E. (cycles 1
and 2) are unclear. However, similar changes in 7-
methyldeoxyguanosine levels have been observed in leucocyte
DNA from patients treated with DTIC, and this was att-
ributed to changes in turnover rates of white blood cell
subpopulations (van Delft et al., 1992).
Of the four patients returning for additional DTIC
therapy, three show an increased 06-MedG AUC with
respect to cycle 1. These values (I.P./2, I.P./3, G.B./2 and
F.E./2) are associated with relatively low pretreatment ATase
levels and form a small cluster in Figure 2c. The effect is
most pronounced in F.E., an individual with brain meta-
stases who received a second course of therapy 8 days after
the initial treatment when 06-MedG was still detectable in
leucocyte DNA (Figure Ic). Presumably, as a consequence of
this, ATase activity remained depressed. Such an explanation
does not apply to the remaining three instances (I.P./2, I.P./3
and G.B./2) as 06-MedG was not detected at the start of856 S.M. LEE et al.
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Figure 2 The relationship between the peak 06-MedG level (a and b) or the 06-MedG AUC (c and d) for leucocyte DNA and
pretreatment ATase (a and c) or ATase depletion (b and d).
subsequent DTIC cycles, suggesting that in some cases ATase
expression does not readily recover.
Clearly, the extent to which these present results can be
extrapolated to tumour cells depends on the extent to which
06-MedG levels in leucocyte DNA correlate with those of
target tumour DNA. Human tissues and tumours differ
greatly in their levels of ATase (D'Incalci et al., 1988), but
there are indications that relationships between tissues may
exist (Kyrtopoulos et al., 1990): studies in rodent models
have shown that DNA methylation occurs to a broadly
similar extent in most tissues following administration of
methylating agents, even those requiring metabolic activation
(Kleihues et al., 1976; Fong et al., 1990), and to a similar
extent in leucocyte DNA (Degan et al., 1988).
In fact, in the present study, the kinetics of lymphocyte
ATase depletion and leucocyte DNA 06-MedG accumulation
does suggest concomitant effects in the two populations of
cells. Following DTIC treatment, correlations were seen
between the amount of 06-MedG formed in leucocyte DNA
(expressed either as the peak value or the AUC) with the
pretreatment lymphocyte ATase activity (Figure 2a and c) or
with the extent of ATase depletion (Figure 2b and d).
Although these relationships are based on a relatively few
patients, a similar trend was observed in a study of patients
treated with the related drug, procarbazine (Souliotis et al.,
1990), and strong correlations between pretreatment ATase
activity and both peak 06-MedG levels and 06-MedG AUC
have recently been established in patients treated with l-p-
carboxyl-3,3-dimethylphenyltriazene (CB10-277; Lee et al.,
1993b; S.M. Lee et al. in preparation). A similar relationship
between ATase activity and the amount of 06-MedG in
DNA was evident also in analyses of bladder mucosa from
individuals exposed to environmental alkylating agents
(Badawi et al., 1991). The present results suggest that
patients with high initial levels of ATase are therefore able to
repair a greater proportion of the 06-MedG resulting from
DTIC therapy, whilst the adduct accumulates in the
leucocyte DNA of individuals with low pretreatment ATase
levels.
Of the eight patients studied, only two (I.P. and K.R.)
responded to therapy and, although 06-MedG AUC for both
patients was close to the mean value, their leucocyte DNA
contained the highest peak levels of 06-MedG after treatment
cycle 1 (Table I). This may reflect the need to reach a
minimum threshold 06-MedG level before cell killing can
occur.
In conclusion, the results reported here lend support to our
earlier suggestion that the nadir lymphocyte ATase depletion
observed approximately 4 h after 400 mg m2 DTIC is a
consequence of DNA methylation, which is also maximal at
this time. The wide individual variations in the extent of
DNA methylation may result not only from differences in
DNA repair capacity but also from differences in the
capacity for metabolic activation, uptake and detoxification
of DTIC. Use of DNA adduct measurement can therefore
provide information on variations in cellular penetration,
metabolic activation, distribution and clearance of
methylating anti-tumour agents such as DTIC, which in com-
bination with knowledge of ATase activity will permit the
design of individualised treatment protocols with improved
therapeutic benefit.
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Abbreviations: ATase, 06-alkylguanine-DNA alkyltransferase; AUC,
area under concentration-time curve; dG, 2'-deoxyguanosine; DTIC
(dacarbazine), 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide;
MTIC, 5-(3-methyl-I-triazeno)imidazole-4-carboxamide; 06-MedG,
06-methyl-2'-deoxyguanosine.
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